Epithalon

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide made of the four amino acids alanine, glutamic acid, aspartic acid and glycine (sequence Ala-Glu-Asp-Gly, short AEDG, CAS 307297-39-8, MW ~390 Da). It was developed in the 1980s at the St. Petersburg Institute of Bioregulation and Gerontology around Vladimir Khavinson and is studied as a short peptide bioregulator modelled on the epithalamin complex originally isolated from bovine pineal glands.

How does Epithalon work?

Epithalon does not bind a classical membrane receptor. Because of its very small size, it appears to be taken up into cells and to interact directly with DNA and transcription factors. Three mechanistic axes dominate the literature:

• Telomerase activation and telomere elongation in cultured human cells (Khavinson 2003, PMID 12937682; Al-Dulaimi 2025, PMID 40908429).
• Normalisation of circadian melatonin release via the pineal gland, especially in older organisms (Korkushko 2007; Ivko 2020).
• Epigenetic regulation of gene expression during neurogenesis and antioxidant effects (Khavinson 2020, PMID 32019204; Araj 2025, PMID 40141333).

What is the evidence?

The evidence base consists mainly of cell culture, animal models and small observational studies - a meaningful share of the older work comes from the Khavinson group itself. Key milestones:

• 2003: Epithalon measurably increases telomerase activity and replicative capacity in human fibroblasts (Bull Exp Biol Med, PMID 12937682).
• 2004: In the same model, Epithalon pushes human somatic cells past the classical Hayflick limit (Bull Exp Biol Med, PMID 15455129).
• 2020: AEDG stimulates gene expression and protein synthesis during neurogenesis, possibly via epigenetic mechanisms (Molecules, PMID 32019204).
• 2022: Epithalon protects mouse oocytes in vitro from post-ovulatory ageing damage (Aging, PMID 35413689).
• 2025: Independent confirmation of telomere elongation across several human cell lines, via both telomerase and ALT (Biogerontology, PMID 40908429).
• 2025: Updated review of the pharmacological evidence (Int J Mol Sci, PMID 40141333).

There is no FDA or EMA approval for Epithalon as a drug. In the US, Epitalon is currently being evaluated under the 503A bulks list process for pharmacy compounding. A Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for 24 July 2026 to discuss safety and possible inclusion on the 503A list.

What is Epithalon researched for?

• Telomere biology and cellular senescence: the main preclinical focus.
• Circadian rhythm: restoration of nocturnal melatonin production in age-related pineal insufficiency.
• In vitro fertilisation: potential protection of oocytes from post-ovulatory ageing (Yue 2022, PMID 35413689; Ullah 2025, PMID 39788414).
• Wound healing in a diabetic retinopathy model (Gatta 2025, PMID 40493162).
• Neurogenesis and cognition: epigenetic regulation of neuronally differentiated cells (Khavinson 2020, PMID 32019204).

How does Epithalon compare to other longevity peptides?

Unlike GH secretagogues such as tesamorelin or the CJC-1295 / ipamorelin stack, Epithalon does not act on the growth hormone axis. It is also not primarily metabolic or lipolytic like AOD-9604. Its focus is cellular senescence, telomere maintenance and circadian regulation. For broader regenerative peptide context, see the recent overview of BPC-157 and GHK-Cu in 2026 research as well as the critical look at the Klow Stack.

Dosing and regulatory status

Epithalon is not an approved drug in the EU, the UK or the US. Peptipedia deliberately does not provide a dosing recommendation. Every dose circulating online originates from uncontrolled reports or from animal work - it is not a recommendation for use.

Safety and open questions

No large randomised phase 3 trials in humans are available. Safety profile, optimal dose, duration of use and long-term risks - in particular the theoretical concern around tumour proliferation through telomerase activation - remain open. An older rat study (Kossoy 2003, PMID 12964022) found no evidence that Epithalon promotes colon carcinogenesis. That is a reassuring signal but not proof of human safety.

Bottom line

Epithalon is a fascinating research molecule sitting at the intersection of telomere biology, pineal function and longevity research. The current evidence is promising but not sufficient for an approval or a therapeutic recommendation. Until larger human studies are published, it remains an experimental peptide.

No medical advice. No dosing or sourcing recommendation. Updated 2026.